

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA HEALTH

China Health Technology Group Holding Company Limited

中國健康科技集團控股有限公司

*(Incorporated in the Cayman Islands with limited liability and formerly known as
China Bozza Development Holdings Limited 中國寶沙發展控股有限公司)*

(Stock code: 1069)

SUPPLEMENTAL ANNOUNCEMENT ON TERMINATION OF VERY SUBSTANTIAL ACQUISITION IN RELATION TO THE ACQUISITION OF 52% EQUITY INTEREST IN THE TARGET COMPANY

References are made to the announcement of China Health Technology Group Holding Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 8 September 2023 regarding a very substantial acquisition in relation to the acquisition of 52% equity interest in the Target Company and the announcement of the Group dated 8 April 2024 in relation to the termination of very substantial acquisition in relation to the acquisition of 52% equity interest in the Target Company (the “**Announcement**”). Unless otherwise defined, terms used herein shall bear the same meanings as defined in the said announcements.

The Board hereby supplement that another important reason for the termination of the Acquisition is that with the development of new projects on the Group’s owned forest land, the Company will establish a new mode of cooperation with Shaanxi Jiashisen Pharmaceutical Investment Company Limited (陝西佳仕森藥業投資有限公司) (“**Shaanxi Jiashisen**”). Shaanxi Jiashisen will provide support for the new projects in terms of quality seedlings, technical consultation, product sales and processing and production of end products. The Board is of the view that the new mode of cooperation will bring more comprehensive and in-depth development to both parties, therefore, the Company and Shaanxi Jiashisen entered into the Termination Agreement.

Saved as disclosed above, all other information as set out in the Announcement remains unchanged and shall continue to be valid for all purposes. This announcement is supplemental to and should be read in conjunction with the Announcement.

As at the date of this announcement, the Company and Shaanzi Jiashisen have not yet entered into any agreement in relation to the new mode of cooperation. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
China Health Technology Group Holding Company Limited
Professor Fei Phillip
Chairman and Executive Director

Hong Kong, 9 April 2024

As at the date of this announcement, the Board comprises Professor Fei Phillip and Mr. Wang Yibin as the executive Directors; and Mr. Guo Zhonglong, Mr. Chau Wing Nam and Ms. Bu Xue as the independent non-executive Directors.